Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-90 SIRT plus low-dose HAIC, TKIs, and ICIs in unresectable large hepatocellular carcinoma
ChiCTR2500106646Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90, oxaliplatin and raltitrexed in hepatocellular carcinoma (HCC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Conversion rate to surgery, Progression-free survival (overall) and 3 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
yttrium-90oxaliplatinraltitrexed
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500106646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106646.